Variation in KSHV prevalence between geographically proximate locations in Uganda

Table 3 Association between KSHV seropositivity or antibody levels and study population. KSHV seropositivity in adults

Study	Females 14-49 years		Females 14–103 years		Males 14–103 years
Study	KSHV seropositivity	*OR (95% CI), P value	KSHV seropositivity	*OR (95% CI), P value	KSHV seropositivity	*OR (95% CI), P value
EMaBS^a	69% (806/1164)	1	69% (806/1164)	1
GPC^b	85% (1388/1638)	2.60 (1.92, 3.51), < 0.0001	87% (1905/2201)	2.61 (1.94, 3.52), < 0.0001	90% (1486/1657)	1
LaVIISWA^c	79% (400/493)	1.69 (1.21, 2.36), 0.002	80% (425/519)	1.72 (1.22, 2.42), 0.002	88% (477/539)	0.71 (0.44, 1.15), 0.165
GHWP^d	90% (361/402)	3.93 (2.74, 5.64), < 0.0001	90% (361/402)	3.9 (2.72, 5.59), < 0.0001

* Adjusted for age group and HIV serostatus. *OR: odds ratio. Logistic regression analysis was used for statistical analysis allowing for the survey design for the LaVIISWA trial. ^aEMaBS-Entebbe Mother and Baby Study, ^bGPC-General Population Cohort, ^cLaVIISWA-Lake Victoria Island Intervention Study on Worms and Allergy related diseases, ^dGHWP-Good Health for Women Project

ISSN: 1750-9378